Skip To Content
JEWISH. INDEPENDENT. NONPROFIT.
Breaking News

Israeli Drug Helps Jimmy Carter Beat Cancer

(JTA) — A drug that was researched and tested in Israel has helped former President Jimmy Carter overcome his life-threatening case of melanoma.

Carter announced on Sunday that the four cancerous lesions on his brain were gone and doctors had found no new signs of cancer growth.

He also said that he will continue taking Keytruda, one of a group of new so-called “immunotherapy” drugs, which aim to help a patient’s immune system defeat the spread of cancer. It was researched by Jacob Schachter at the Sheba Medical Center in Ramat Gan, Israel.

Keytruda helps immune system cells identify and destroy tumor cells, which usually pass by them undetected. This bolstering of the immune system is a break from the theory behind chemotherapy, which is designed to destroy cancerous cells but also destroys healthy ones.

Carter, 91, has said that he has experienced no side effects to Keytruda.

“The new drug creates real potential for curing one of the deadliest forms of cancer, at the negligible cost of light and tolerable side effects,” Schachter, a professor and head of the Ella Institute for Melanoma at the Sheba Medical Center, told Ynet last year. “Among doctors, too, the scope of the breakthrough has yet to be digested.”

Carter announced in August that he had stage 4 melanoma that had spread across his body.

However, cancer experts told NBC News that it is not completely clear whether the drug cured Carter on its own, and that advanced forms of the cancer have been known to disappear and return. The former commander-in-chief was also treated with traditional radiation and had a tumor on his liver removed.

A message from our CEO & publisher Rachel Fishman Feddersen

I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward’s award-winning, nonprofit journalism during this critical time.

At a time when other newsrooms are closing or cutting back, the Forward has removed its paywall and invested additional resources to report on the ground from Israel and around the U.S. on the impact of the war, rising antisemitism and polarized discourse..

Readers like you make it all possible. Support our work by becoming a Forward Member and connect with our journalism and your community.

—  Rachel Fishman Feddersen, Publisher and CEO

Join our mission to tell the Jewish story fully and fairly.

Republish This Story

Please read before republishing

We’re happy to make this story available to republish for free, unless it originated with JTA, Haaretz or another publication (as indicated on the article) and as long as you follow our guidelines. You must credit the Forward, retain our pixel and preserve our canonical link in Google search.  See our full guidelines for more information, and this guide for detail about canonical URLs.

To republish, copy the HTML by clicking on the yellow button to the right; it includes our tracking pixel, all paragraph styles and hyperlinks, the author byline and credit to the Forward. It does not include images; to avoid copyright violations, you must add them manually, following our guidelines. Please email us at [email protected], subject line “republish,” with any questions or to let us know what stories you’re picking up.

We don't support Internet Explorer

Please use Chrome, Safari, Firefox, or Edge to view this site.